The market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), has great untapped potential owing to the lack of approved treatment options and the…
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…
Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the…
Scleroderma, also known as systemic sclerosis (SSc), is a rare, progressive, and debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that…
Clarivate Epidemiology’s coverage of nonalcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the…
The market for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity for drug developers owing to the lack of…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; such mutations lead…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; such mutations lead…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…